Cargando…
Serum Epiplakin Might Be a Potential Serodiagnostic Biomarker for Bladder Cancer
SIMPLE SUMMARY: Improving early diagnosis and long-term postoperative monitoring of bladder cancer has become a focus of international research. In the present study, we evaluated the epiplakin expression levels in sera from patients with bladder cancer via a micro-dot blot array. Serum epiplakin le...
Autores principales: | Shimura, Soichiro, Matsumoto, Kazumasa, Shimizu, Yuriko, Mochizuki, Kohei, Shiono, Yutaka, Hirano, Shuhei, Koguchi, Dai, Ikeda, Masaomi, Sato, Yuichi, Iwamura, Masatsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534213/ https://www.ncbi.nlm.nih.gov/pubmed/34680299 http://dx.doi.org/10.3390/cancers13205150 |
Ejemplares similares
-
DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer
por: Hirano, Shuhei, et al.
Publicado: (2022) -
Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2022) -
Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy
por: Koguchi, Dai, et al.
Publicado: (2021) -
Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
por: Koguchi, Dai, et al.
Publicado: (2022) -
Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy
por: Katsumata, Hiroki, et al.
Publicado: (2023)